



IFW

PATENT
Attorney Docket No. 056291-5262

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lee NEWTON <i>et al.</i>)	Confirmation No.: 6386
)	
Application No.: 10/537,723)	Group Art Unit: 1624
)	
Filed: June 7, 2005)	Examiner: <i>Unassigned</i>
)	
For: PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS)	Date: January 26, 2007

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed


invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: **January 26, 2007**
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:



Gregory T. Lowen
Registration No. 46,882
Tel. No.: (202) 739-5915
Fax No.: (202) 739-3001

PIPE (Use several sheets if necessary)

PTO Form 1449
January 26, 2007

Application No.
10/537,723

Filing Date: June 7, 2005

Group Art Unit: 1624

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
---------	--------------	------	------	-------	-----------	-------------

		Document No.	Date	Country	Class	Sub-Class	Translation
--	--	--------------	------	---------	-------	-----------	-------------

/EL/	1.	WO 2004/054986	July 1, 2004	WIPO			

/EL/	2.	Hannah et al. "Structural studies on bioactive compounds. Part 29: palladium catalysed arylations and alkynylations of sterically hindered immunomodulatory 2-amino-5-halo-4,6-(disubstituted)pyrimidines" Bioorg Med Chem. 8(4):739-750 (2000)
/EL/	3.	Hauser et al. "Synthesis of 5-phenyl-4,6-dimethyl-2-pyrimidol and derivatives from the cyclization of urea with 3-phenyl-2,4-pentanedione" Journal of Organic Chemistry 18(5): 588-593 (1953)

11/08/2008

1-WA/2693347.1